Vol. 17/No. 18 | OncologyLive

5 Key Areas in Emerging Immunotherapy Research Stand Out

September 24, 2016

Although checkpoint blockade inhibitors targeting the PD-1/PD-L1 pathway are currently dominating the oncology community's attention, there are many other exciting approaches to anticancer immunotherapy being explored in a range of solid tumors

Vital Molecular Differences Found in Neuroendocrine Tumor Subtypes

September 23, 2016

A genomic analysis of poorly differentiated neuroendocrine tumors from primary lung and gastrointestinal sites underscores the diversity of these tumors and the evolving need to move toward precision medicine when it comes to treating patients with these malignancies.

Fresh Strategies Aimed at Taming GVHD

September 20, 2016

Approaches to reducing and preventing graft-versus-host-disease are being explored, including the development of ruxolitinib (Jakafi) and ibrutinib (Imbruvica) under breakthrough therapy designations.

The Jury's Still Out on Whole-Brain Radiation Therapy for Brain Metastases

September 20, 2016

Despite the fervent advocacy of stereotactic radiosurgery alone, the addition of whole-brain radiation therapy clearly improves local control, decreases distant brain failure, minimizes the need for salvage therapies such as surgery, and, most importantly, decreases neurologic death.

Innovative Clinical Trial Designs Generate New Ethical Dilemmas

September 16, 2016

Fifty years after Henry Beecher’s landmark critique finally helped begin breaking the “code-of-silence” regarding the conduct of unethical clinical research in the United States—sadly including the oncology arena—many serious concerns linger.

Leading Researchers Dissect PD-1/PD-L1 Evidence in NSCLC

September 15, 2016

Although lung cancer remains the leading cause of cancer-related mortality in the United States and 5-year survival rates are low at 17.8%, the grim picture for this tumor type is starting to shift to a more hopeful one as its biology is becoming better understood, facilitating treatment selection and providing researchers with new therapeutic targets.

Genomic Differences in Prostate Cancer Stages Are Coming Into Focus

September 13, 2016

Prostate cancer is slow-growing and readily curable in many cases, but the propensity for some tumors to develop into an aggressive, metastatic form that becomes resistant to androgen-targeting therapies continues to present a significant obstacle.